Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer

L. Repetto, L. Miglietta, G. Gardin, C. Naso, S. Giudici, L. Merlini, P. Queirolo, E. Campora, P. Pronzato, R. Rosso

Research output: Contribution to journalArticlepeer-review


Forty-three evaluable patients with advanced breast cancer were treated with a combination of mitoxantrone 10 mg/sqm and mitomycin C 10 mg/sqm every 3 weeks. Two patients (4%) achieved objective responses lasting 3 and 16 months. The median duration of survival after protocol entry was 6 months (range 1-22) and the median progression-free survival was 3.5 (range 1-20). Only mild toxicities were observed. We concluded that the mitoxantrone and mitomycin C combination has limited toxicity but low activity and only brief disease palliation in advanced breast cancer.

Original languageEnglish
Pages (from-to)165-166
Number of pages2
JournalAnnals of Oncology
Issue number2
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer'. Together they form a unique fingerprint.

Cite this